Piramal Pharma Limited — Updates, 28-01-2025: Press Release

Piramal Pharma Limited has released its financial results for the third quarter and nine months of FY25, showcasing a solid performance. Consolidated revenue grew by 13% year-over-year to ₹2,204 Cr for Q3 and 14% to ₹6,397 Cr in the nine-month period. The CDMO segment led growth, achieving 18% revenue growth, while the Complex Hospital Generics segment also showed a recovery with 14% growth. Notably, EBITDA rose by 20% YoY for the nine months, indicating strong operational efficiency and cost optimization efforts, despite a net profit drop due to exceptional items in the previous year.

Piramal is making strides in sustainability by converting the Digwal facility's coal-fired boiler to a biomass briquette system, expected to cut GHG emissions significantly. With ongoing expansions in capacity and product offerings, along with a strong market position in key segments, the company has a positive outlook as it targets sustained growth in the evolving pharmaceutical landscape. Investors should monitor the recovery trajectory in the CHG segment, which remains critical for overall performance.